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Purpose: A key property to consider in all genetic tests is clinical
utility, the ability of the test to influence patient management and
health outcomes. Here we assess the current clinical utility of
genetic testing in diverse pediatric inherited eye disorders (IEDs).
Methods: Two hundred one unrelated children (0–5 years old)
with IEDs were ascertained through the database of the North West
Genomic Laboratory Hub, Manchester, UK. The cohort was
collected over a 7-year period (2011–2018) and included 74
children with bilateral cataracts, 8 with bilateral ectopia lentis, 28
with bilateral anterior segment dysgenesis, 32 with albinism, and 59
with inherited retinal disorders. All participants underwent panel-
based genetic testing.
Results: The diagnostic yield of genetic testing for the cohort was
64% (ranging from 39% to 91% depending on the condition). The
test result led to altered management (including preventing
additional investigations or resulting in the introduction of
personalized surveillance measures) in 33% of probands (75% for
ectopia lentis, 50% for cataracts, 33% for inherited retinal disorders,
7% for anterior segment dysgenesis, 3% for albinism).
Conclusion: Genetic testing helped identify an etiological
diagnosis in the majority of preschool children with IEDs. This
prevented additional unnecessary testing and provided the
opportunity for anticipatory guidance in significant subsets of
patients.
Genetics in Medicine (2020) 22:745–751; https://doi.org/10.1038/s41436-
019-0722-8
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INTRODUCTION
Inherited eye disorders are an important cause of visual
impairment in children and young adults.1 Prevalent subtypes
include inherited retinal disease (IRD), pediatric cataracts,
ocular anterior segment dysgenesis (ASD), and albinism.
These conditions may manifest as isolated ophthalmic
disorders (nonsyndromic forms) or as part of multisystemic
syndromes that include extraocular features (syndromic
forms). In the latter scenario, ocular manifestations are often
one of the first presenting features of a syndrome (e.g.,
individuals with Marfan syndrome often present with ectopia
lentis).2–6
In the past three decades, over 400 genes have been found
to be associated with inherited eye disorders. Such advances in
delineating the molecular pathology of these conditions,
together with breakthroughs in DNA sequencing technolo-
gies, catalyzed the development of powerful genomic tests.3,7
These tests have revolutionized diagnostics for many inherited
eye disorders and, in 2012, the American Academy of
Ophthalmology published guidelines encouraging their rou-
tine use for a number of these conditions.8 Despite this,
variation in the current provision of genetic testing remains
significant.9 Considering economic factors is necessary but
insufficient and one way to address this variation is by
continuing to accrue robust evidence of benefit.
In 2017, the US National Academies of Sciences, Engineer-
ing, and Medicine published a report on how evidence on the
usefulness of genetic tests is generated and evaluated.10 A key
concept in this document is clinical utility, defined as “the
ability of a test to improve clinical outcomes measurably and
add value for patient management decision making compared
with current management without genetic testing.”10 Over the
past decades, this term has been construed both narrowly and
broadly. In its narrowest sense, it refers to the ability of a test
to lead to an improved health outcome (e.g., impact on
mortality, morbidity, or visual disability). A broader
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definition includes any change in management (e.g., prevent-
ing additional investigations or introducing surveillance
measures) while the broadest definition encompasses any
outcome that is important to the affected individual or family
(e.g., early resolution of uncertainty, better understanding of
the condition, effect on reproductive or life planning).9,11,12
The primary focus of previous studies has been the evaluation
of specific test parameters such as analytical validity (i.e., the
ability to accurately identify variants of interest; associated
with technical performance) and clinical validity (i.e., the
ability to detect the clinically defined disorder of interest;
associated with the diagnostic yield).3,7,13–15 As a result, data
on how genetic tests influence patient management and
health outcomes in different clinical scenarios are scarce.
The aim of this study was to assess the current clinical
utility of diagnostic genetic testing in infants and young
children (aged 0–5 years) with different inherited eye
disorders (including bilateral pediatric cataracts, bilateral
ectopia lentis, bilateral ASD, albinism, and IRD). The
potential to inform management and to allow the definition
of specific care pathways is highlighted.
MATERIALS AND METHODS
Participants
Study subjects were retrospectively ascertained through the
database of the North West Genomic Laboratory Hub,
Manchester, UK. Only children who were diagnosed through
the tertiary pediatric ophthalmic genetics service at Manche-
ster University NHS Foundation Trust, Manchester, UK were
included. The families who chose to undergo genetic analysis
were offered pretest counseling and provided written
informed consent.
Probands selected for study were unrelated and had to meet
the following inclusion criteria:
● To be five years of age or less at the time of referral for
genetic testing.
● To be referred for genetic testing between September 2011
and August 2018 (i.e., over a 7-year period).
● To have one of the following clinical diagnoses: bilateral
pediatric cataracts, bilateral ectopia lentis, bilateral ASD
(including pediatric primary glaucoma), albinism (ocular
or oculocutaneous), and IRD.
A subset of the cases included in this study has been
previously reported (see Supplementary Table 1 for more
information).2,3 Ethics committee approval for the study was
obtained from the North West Research Ethics Committee
(11/NW/0421 and 15/YH/0365) and all investigations were
conducted in accordance to the tenets of the Declaration of
Helsinki.
Phenotypic data collection
The clinical notes and/or electronic health-care record entries
were reviewed for each study participant. The clinical
impression at the time of referral for genetic testing was
recorded. The outcome of the consultation in which the
genetic test results were discussed was also noted (including
information on referrals to other subspecialties and discus-
sions around prognosis and family planning).
A full clinical history was obtained for each proband and all
study subjects were examined by a consultant ophthalmolo-
gist. A subset of participants underwent fundus imaging, and
electrodiagnostic testing was performed in most children with
a suspected diagnosis of albinism or IRD using previously
described methods.2 Where extraocular features were present
or suspected, a full systemic assessment was undertaken by a
consultant clinical geneticist.
Clinical genetic testing and bioinformatic analysis
Blood samples were obtained from all probands and DNA
was extracted. Multigene panel testing and analysis were
subsequently performed at the North West Genomic
Laboratory Hub (ISO 15189:2012; UKAS Medical reference
9865). DNA samples were processed using Agilent SureSelect
(Agilent Technologies, Santa, Clara, CA) target enrichment
kits designed to capture all exons and 50 base pairs of flanking
intronic sequences of selected panels of genes. The decision
on which panel to use was made by the referring clinician
(either a consultant pediatric ophthalmologist or a consultant
clinical geneticist with an interest in ophthalmic genetics). In
general, the following panels were available (see also
Supplementary Tables 2–7):
● For pediatric cataract and ectopia lentis: either 1143 (n=
46) or 144 (n= 31) or 12 (n= 1) genes.
● For ASD: either 1143 (n= 3) or 45 (n= 22) or 32 (n=
2) genes.
● For suspected albinism: 18 (n= 30) or 26 (n= 1) or 40
(n= 1) genes.
● For IRD: either 10516 (n= 14) or 17717 (n= 43) genes.
Notably, 7 probands underwent genome sequencing using a
previously described approach.15 Information on the exact
panel test that was performed in each study participant can be
found in Supplementary Table 1. Additionally, 18 probands
with a diagnosis of syndromic inherited eye disease were
tested using a DNA microarray assay while 4 probands had
cytogenetic chromosomal analysis. A list of all the relevant
transcripts/genes can be found in Supplementary Tables 2–7.
Sequencing, bioinformatic analyses, and clinical interpreta-
tion were performed as previously described.2,3,15–17 A
pathogenicity classification score was assigned to each rare
variant after in silico modeling and appraisal of the scientific
literature. A clinical report was then generated and variants
that could account for the tested individual’s phenotype were
highlighted. Reports were then discussed in monthly multi-
disciplinary team meetings.
For the purpose of this study, subjects were split into two
groups:
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● Probable molecular diagnosis group: probands with
clearly or likely pathogenic variant(s) in an apparently
disease-causing state (e.g., ≥1 variant in a gene linked with
dominant disease or ≥2 variants in a gene linked with
recessive disease).
● Unknown molecular diagnosis group: all other probands.
We defined “diagnostic yield” as the percentage of
individuals with a particular phenotype who received a
probable molecular diagnosis.10
RESULTS
Overall, 201 (120 male, 81 female) unrelated infants and
young children (0–5 years at the time of genetic testing) met
the inclusion criteria for the study. Median age at referral for
genetic testing was 3 years. The breakdown of the 201 study
participants among high order diagnostic categories is shown
in Table 1. Extraocular features were noted at the time of
referral for genetic testing in 33/201 cases (16%) while a
relevant family history was recorded at the time of referral for
genetic testing in 31/201 cases (15%).
Diagnostic yield
A probable molecular diagnosis was identified in 129/201
probands (64%); the diagnostic yield of genetic testing for
each condition is shown in Table 1 and the genetic findings
are presented in detail in Supplementary Table 1. There was
significant genetic heterogeneity. Genes found to be mutated
in ≥1% of the cohort (i.e., in >2 probands) are shown in
Table 2. Defects in these 14 genes were collectively responsible
for disease in 71/201 probands (35%). In contrast, 33 genes
were associated with disease in a single family each (33/201
probands; 16%).
Among the individuals reported to have extraocular
features at the time of referral for genetic testing, a probable
molecular diagnosis was identified in 13/33 (39%). For
individuals with a known family history, the diagnostic yield
was 23/31 (74%).
Clinical utility
The genetic test result informed/altered management in 66/
201 probands (33%). The following scenarios were identified:
● Avoiding additional unnecessary tests.
● Initiating surveillance for extraocular manifestations
(referral to another subspecialty).
● Reducing prognostic uncertainty (distinguishing station-
ary from progressive conditions).
● Determining eligibility for clinical trials of gene-based
therapeutic interventions.
The number of individuals impacted per diagnostic
category is shown in Table 3. More details on the exact
management change for each patient can be found in
Supplementary Table 1. Two illustrative cases are presented
in the following section.
Most probands had no known family history of relevance
(170/201; 85%). In these simplex cases the inheritance pattern
is unclear without a molecular diagnosis, and genetic testing is
required to refine the risk to future pregnancies and family
members. Among the simplex cases who were found to have a
probable molecular diagnosis (106/170), 69% (73/106) had
autosomal recessive, 23% (24/106) had autosomal dominant,
and 8% (9/106) had X-linked inheritance (Supplementary
Table 8). Six study participants were shown to have a de novo
variant in a gene associated with autosomal dominant or X-
linked inheritance (which suggested that the risk to future
pregnancies of the parents is low).
Two illustrative cases
Proband 18014933 was diagnosed with bilateral dense
nuclear cataracts at day 1 of age. She was otherwise a
Table 1 Breakdown among diagnostic categories, and
percentage of study participants in each category for which







Bilateral pediatric cataracts 74 50% (37/74)
Bilateral ectopia lentis 8 75% (6/8)




Albinism 32 91% (29/32)
Inherited retinal disease 59 78% (46/59)
aWe considered probands to have probable molecular diagnosis when they car-
ried clearly or likely pathogenic variant(s) in an apparently disease-causing state
(e.g., ≥1 variant in a gene linked with dominant disease or ≥2 variants in a gene
linked with recessive disease). Further information can be found in “Materials and
Methods” and in Supplementary Table 1.
Table 2 Genes found to be mutated in ≥1% of the cohort.
Gene name Number of probands
in the whole cohort
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healthy infant and there was no family history of visual
problems. Lensectomy procedures were performed at 7 weeks
of age. Genetic testing was requested prior to surgery and the
c.2317G>A p.(Gly773Arg) variant was identified in the
COL4A1 gene in heterozygous state. Testing of parental
samples suggested that this variant might have occurred de
novo. COL4A1 encodes the α1 chain of type IV collagen and
defects in this gene have been linked to a multisystem
disorder that is generally characterized by the presence of
cerebrovascular disease with variable ocular, renal, and
muscular involvement [MIM 175780].18 Cerebrovascular
manifestations occur from fetal life onward and their
severity may range from small vessel brain disease to fatal
cerebral hemorrhage.19 Ocular abnormalities are variably
observed and may include pediatric cataract, ASD, or retinal
arterial tortuosity.20 Notably, a family with isolated pediatric
cataract has been reported.21 Kidney disease (hematuria and
renal cysts of variable severity) and painful muscle cramps
occur in subsets of affected individuals.18 Referrals were
made to establish the extent of disease in proband 18014933;
no developmental delay, cardiac abnormalities, seizures, or
other extraocular features were present as of age 1.5 years.
Proband 17028507 was diagnosed with oculocutaneous
albinism at 4 months of age. He presented with nystagmus,
iris transillumination, fundal hypopigmentation, and foveal
hypoplasia. There was moderate amount of skin and hair
pigmentation, there were no other concerns about his health
or development, and there was no family history of albinism
or visual problems. Genetic testing was requested at 4 months
of age revealing a c.1507G>T p.(Glu503Ter) variant in HPS5
in homozygous state. HPS5 encodes a protein that has a role
in the intracellular trafficking of proteins.22 Defects in this
gene have been found to cause Hermansky–Pudlak syndrome
(HPS), a multisystem disorder characterized by albinism and
bleeding diathesis. Granulomatous colitis and pulmonary
fibrosis can also be features of this condition although HPS5
is associated with a less severe form of HPS with only mild
bleeding tendency and no gastrointestinal or pulmonary
symptoms [MIM 614074].23 Proband 17028507 was referred
to hematology and platelet function analysis was found to be
abnormal: there was prolonged Platelet Function Analyzer-
100 (PFA-100) closure time following stimulation with
collagen and epinephrine (>300 seconds; reference range
79–205 seconds). This finding had significant implications as
the child was due to have a routine urological procedure
(orchidopexy) that was safely performed with appropriate
precautions (including oral transexamic acid commenced 24
hours prior to the procedure and continued for 5 days,
intravenous desmopressin acetate [DDAVP] perioperatively,
and HLA matched platelets available to be used in the event
of unexpected bleeding).
DISCUSSION
In this study, we provide evidence in support of routine
genetic test provision for specific inherited eye disorders
(bilateral pediatric cataracts, bilateral ectopia lentis, bilateral
ASD, albinism, and IRD) in children aged 0 to 5 years. The
diagnostic yield of panel-based genetic testing in this cohort
of 201 probands was 64% (ranging from 39% to 91%
depending on the condition; Table 1) and the test result led
to altered management in significant subsets of children
(ranging from 3% to 75% depending on the condition;
Table 3).
The diagnostic rates in this cohort of infants and young
children were compared with previous studies with less strict
inclusion criteria. For bilateral pediatric cataracts we identi-
fied a probable molecular diagnosis in 50% of cases; this is one
of the largest cohorts of individuals with this phenotype
reported to date (n= 74; Table 1). Two previous studies on
congenital cataract from Australia reported diagnostic yields
of 62% (n > 33)24 and 68% (n= 46);25 a study from Saudi
Arabia reported a diagnostic yield of 58% (n= 74)26 and five
further studies on Chinese cohorts reported diagnostic yields
of 26% (n= 74),27 59% (n= 39),28 62% (n= 21),29 63% (n=
27),30 and 68% (n= 34).31 For bilateral ectopia lentis we
identified a probable molecular diagnosis in 75% of a
relatively small cohort (n= 8; Table 1). Previous studies from
the Netherlands, the UK, and China reported diagnostic yields












Bilateral pediatric cataracts 50% (37/74)a 12% (9/74) – –
Bilateral ectopia lentis 50% (4/8) 25% (2/8) – –
Bilateral ocular anterior segment
dysgenesis (including pediatric primary
glaucoma)
4% (1/28) 4% (1/28) – –
Albinism – 3% (1/32) – –
Inherited retinal disease – 8% (5/59) 25% (15/59) 3% (2/59)
Overall 21% (42/201) 9% (18/201) 7% (15/201) 1% (2/201)
Further information can be found in the illustrative cases presented in “Results” and in Supplementary Table 1.
aThis figure is based on the fact that there was no need to perform the conventional biochemical tests for individuals with a known molecular diagnosis.
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of 67% (n= 24),32 72% (n= 18),6 and 85% (n= 40)33
respectively. In children with bilateral ASD, we identified a
probable molecular diagnosis in 39% of cases (n= 28; 16/28
only had glaucoma with no other features of ASD—the yield
for this subset was 31%; Table 1). A recent UK study of
children with this clinical presentation reported a diagnostic
yield of 25% (n= 113; 60/113 only had glaucoma with no
other features of ASD—the yield for this subset was 13%).34
For albinism, we identified a probable molecular diagnosis in
91% of cases (n= 32; Table 1); a large study from France
summarizing data from 990 probands with albinism reported
a diagnostic yield of 72% (n= 990).4 For IRD, we identified a
probable molecular diagnosis in 78% of cases (n= 59;
Table 1). A previous study on pediatric IRD from our group
reported a diagnostic yield of 79% (n= 85)2 while a landmark
study on 1000 patients with IRD (aged ≤60 years) reported a
diagnostic yield of 76% (n= 1000).7 Also, a recent study
reporting findings from 1243 IRD patients of Chinese origin
reported a diagnostic yield of 72% (n= 1243).35 Overall, these
comparisons suggest that the likelihood of a genetic test
identifying a molecular diagnosis are linked to (1) the current
state of knowledge of the genetic architecture of the patient’s
condition (e.g., higher for albinism and IRD than for cataract
and ASD); (2) the pretest probability of the patient having a
penetrant monogenic disorder (typically higher for bilateral
disease, when there is relevant family history, for specific well-
recognized clinical presentations and/or for early childhood
onset conditions).35,36
Like any other medical interventions, diagnostic genetic
tests should be thoroughly evaluated before their introduction
into routine practice. Increasingly, decision makers request
more than measures of a test’s technical performance and
diagnostic yield; clinical utility has therefore emerged as a key
concept.9,10 Clinical utility is contextual and we have studied
different clinical scenarios in a population of children aged 0
to 5 years.
For bilateral congenital cataract, previous studies have
highlighted how genetic testing can help identify clinically
unrecognized syndromic associations (e.g., when the clinical
signs are subtle or still evolving); examples include oculofa-
ciocardiodental syndrome (BCOR-related disease [MIM
300166]),25,28 Nance–Horan syndrome [MIM 302350],25,31
and certain metabolic conditions (some of which are
treatable).37 In this study, genetic testing pointed to a
previously unsuspected syndrome in 12% (9/74) of cases
(Table 3; Supplementary Table 1). Intriguingly, 4 of these 9
probands had COL4A1-related disorders [MIM 175780] and
were therefore at risk of small vessel brain disease.20 Another
important finding was that additional tests were avoided in
50% (37/74) of cataract probands: since a molecular diagnosis
was identified in these children there was no need for further
diagnostic work-up. It is noteworthy that clinical utility
cannot be defined in an absolute sense and has to be evaluated
relative to a comparator strategy.10 Traditionally, children
with bilateral cataracts without a family history had a number
of investigations (including chromosomal analysis, extensive
biochemical tests, and tests looking for evidence of intrauter-
ine infection).3 We have previously reported that genetic
analysis has significant advantages compared with this
traditional approach,38 suggesting that the above clinical
utility estimate is conservative. Overall, we provide further
evidence supporting a central role of genetic testing to the
care pathway of children with cataract.
For ectopia lentis, genetic testing is particularly helpful in
confirming or excluding FBN1-associated disorders (including
Marfan syndrome). In this cohort, 2/8 children were initially
diagnosed with apparently isolated ectopia lentis but were
found to carry FBN1 variants and thus benefited from regular
surveillance for aortic root disease. In contrast, 4/8 children
had a different molecular diagnosis (recessive ADAMTSL4- or
recessive LTBP2-related disease [MIM 225100, 225200 and
251750]; Supplementary Table 1) and did not require
extensive systemic investigations. Our findings are in keeping
with previous studies and highlight that recessive “isolated”
ectopia lentis is a frequent cause and an important differential
for this clinical presentation in children.6,32
ASD encompasses a variety of clinical presentations5 and
the clinical utility of genetic testing within this diagnostic
category is not uniform. For suspected pediatric primary
glaucoma, genetic analysis can help exclude secondary causes.
Interestingly, two infants from this cohort who were initially
diagnosed with primary glaucoma were found to have a
secondary mechanism associated with either LTBP2 or
FOXC15 gene defects. Furthermore, one infant who presented
with apparently isolated primary glaucoma was found to have
Charcot–Marie–Tooth hereditary neuropathy (type 4B2
[MIM 604563]) (Supplementary Table 1). For ASD without
glaucoma, there is a growing body of evidence suggesting that
the glaucoma risk differs among different genetic causes.39 For
aniridia, genetic testing is particularly important as it allows
early detection/exclusion of two molecular subtypes (account-
ing for ~10% of aniridia cases) that are associated with life
limiting complications: WAGR syndrome [MIM 194072] and
ACTA2-related multisystemic smooth muscle dysfunction
[MIM 613834].40
For albinism, it is known that syndromic forms of the
disease (HPS and Chediak–Higashi syndrome [MIM 214500])
can be overlooked, especially in young children. Affected
individuals may therefore remain undiagnosed until later in
life unless genetic testing is performed; this is concerning as
these patients require specific management to prevent life
limiting complications.4 In this study we found that 3% (1/32)
of children with presumed nonsyndromic albinism had HPS
(proband 17028507, discussed in the “Results” section).
Although we identified just a single case, our findings are in
general in agreement with a large study in the French
population that reported syndromic forms in 5% of all
albinism cases (46/990 HPS, 2/990 Chediak–Higashi syn-
drome [MIM 214500]).4 Another finding in the present study
is that genetic testing helped refine the diagnosis in three
males who were clinically diagnosed with “ocular albinism”
(Supplementary Table 1). This clinical presentation may be
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due to X-linked ocular albinism (GPR143 gene defects [MIM
300500]), hypomorphic variants in genes associated with
oculocutaneous albinism, variants in SLC38A8 (causing foveal
hypoplasia and optic nerve decussation defects [MIM
609218]), or mild forms of HPS (e.g., HPS3 [MIM 614072],
HPS5 [MIM 614074] and HPS6 [MIM 614075]).4 Of these
three male probands, one had X-linked ocular albinism [MIM
300500] and two had partial oculocutaneous albinism. This
result led to tailored advice on skin photoprotection and on
the risk for developing nonmelanoma skin cancer.
For IRD, a key driver for genetic testing is the advent of
gene-directed interventions including gene augmentation
therapies and antisense oligonucleotide treatments.41 Clinical
trials for multiple IRD subtypes are in progress and genetic
analysis is required to identify those for whom these
treatments might be relevant. Furthermore, IRD can be one
of the first presenting features of a syndromic condition such
as a ciliopathy (e.g., Bardet–Biedl, Alström [MIM 203800], or
Senior-Løken syndrome) or a neurometabolic disorder (e.g.,
Refsum [MIM 266500] or Batten [MIM 204200] disease). In
this cohort, 6% (3/48) of probands had a clinical diagnosis of
nonsyndromic IRD but were found to have defects in CEP290,
a ciliopathy gene that is often associated with extraocular
manifestations.42 Referrals for further investigations were
initiated revealing no relevant systemic manifestations to date.
Notably, two previous studies reported that genetic analysis
revealed the presence of a syndromic disorder in 1% (3/218)13
and 2% (2/85)2 of unselected IRD patients (all these 5 cases
were initially thought to have nonsyndromic disease). In
addition to highlighting the possibility of extraocular involve-
ment, genetic testing can help differentiate progressive from
stationary IRD subtypes.2 Here, we found that genetic testing
helped reduce prognostic uncertainty in 25% (15/59) of study
participants. Interestingly, approximately 1 in 4 children in
whom a progressive disorder was strongly considered were
shown to have a stationary condition (Supplementary Table 1).
There are some important caveats that are worth high-
lighting. First, the utility of genetic testing has different
dimensions (public health, clinical, personal, societal) and
focusing only on management change is insufficient. We
believe that there is great value in establishing a molecular
diagnosis even when there is no direct impact on manage-
ment. A precise diagnosis can not only lead to early resolution
of uncertainty and better understanding of the condition but
it also can inform reproductive and life planning. However,
outcomes such as well-being, quality of life, and impact on
family members have a degree of subjectivity that makes
devising appropriate measures and research designs challen-
ging.10 Second, the ability of a positive test result to inform
clinical practice is only one aspect of clinical utility. A more
complete assessment would involve evaluating the balance of
health benefits and potential harms that accrue from positive
and negative results. A positive test result could lead to
anxiety, “overdiagnosis,” and unnecessary treatment while a
negative result can make the tested individual feel disap-
pointed and demotivated. To minimize these risks, careful
pretest counseling and a narrow pretest clinical hypothesis
(that reduces the false discovery rate)7 are required. Third, it
is worth noting that clinical utility is typically based on the
utility of the intervention guided by the test, rather than the
test itself (e.g., excision of a Wilms tumor following a genetic
test for aniridia). However, the evidence for many such
interventions is not robust (e.g., β-blocker initiation to
prevent aortic dissection in patients with Marfan syndrome).
There is a need for well-defined protocols that link test results
to specific clinical responses and downstream management
(e.g., screening protocols for renal disease in individuals with
defects in ciliopathy genes). These protocols should be based
on current best evidence and the generated data should be
used as a basis for further evidence generation. Finally, we
note that the ideal study design for assessing clinical utility is a
randomized controlled trial (as this design maximizes internal
validity and addresses issues of selection bias and confound-
ing). However, for each test, the required level of evidence
depends on the clinical indication and setting. Although this
retrospective observational study is experimentally less
rigorous compared with a prospective randomized trial, it
allowed collection of data on long term outcomes and it is
arguably more representative of real-world clinical care
(making its results more likely to be generalizable).
In summary, this study highlights the potential of genetic
testing to deliver a precise diagnosis with a high success rate
in infants and young children suspected to have an inherited
eye disorder. Genetic testing can point to mild, unrecognized,
or previously disregarded syndromic features. This often leads
to downstream clinical management that can have important
implications for the child’s health and development. Our
findings provide further evidence in support of the use of
genetic testing as a frontline diagnostic tool for bilateral
pediatric cataracts, bilateral ectopia lentis, bilateral ASD,
albinism, and IRD.
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